CALR突变蛋白恢复MPL p.R464G变异相关CAMT对艾曲泊帕的应答
该研究报告一个近亲家系中导致先天性无巨核细胞性血小板减少症(CAMT)的新纯合MPL变异(MPL R464G),该变异使受体滞留在内质网、血小板表面表达降低。过表达骨髓增殖性肿瘤相关CALR突变不能纠正MPL R464G的转运或诱导组成性信号,但意外恢复了对艾曲泊帕(ELT)而非TPO的正常应答;患者CD34+细胞的内源性CALR突变在ELT作用下恢复了巨核细胞分化。
要点
- MPL R464G纯合变异导致CAMT,受体成熟缺陷并滞留于内质网,血小板表面表达降低。
- MPL R464G对TPO刺激信号有限;CALR突变不纠正转运但恢复对艾曲泊帕的应答。
- 患者CD34+细胞内源性CALR突变在艾曲泊帕作用下恢复巨核细胞分化。
核心结论
- MPL R464G是导致CAMT的新纯合变异,其受体成熟缺陷使表面表达降低。
- MPL相关CALR突变不能挽救MPL R464G的转运或诱导组成性信号,但可恢复对艾曲泊帕的应答。
研究设计与样本
- 研究报告1个近亲家系中导致CAMT的新纯合MPL变异,先证者及其姐妹表现为重度血小板减少伴轻度贫血。
- 采用下一代测序鉴定变异,并在细胞系及患者CD34+细胞中进行功能研究。
主要发现
- 先证者及其姐妹携带纯合MPL R464G变异,血小板表面受体表达弱。
- 细胞系中MPL R464G成熟缺陷并滞留于内质网,表面表达低导致TPO刺激信号非常有限,细胞存活并增殖减少。
- 过表达MPN相关CALR突变不挽救MPL R464G向细胞表面的转运,也不诱导组成性信号。
- CALR突变意外恢复对艾曲泊帕而非TPO的正常应答,纯化重组CALR突变蛋白仅部分模拟该效应。
- 内源性CALR突变可恢复携带MPL R464G的患者CD34+细胞在ELT作用下的巨核细胞分化。
临床怎么用
- 对于MPL R464G相关CAMT,艾曲泊帕可能通过CALR突变蛋白的作用恢复治疗应答。
- 该发现提示CALR突变状态可能影响艾曲泊帕对MPL变异相关CAMT的疗效。
局限性
- 研究基于1个近亲家系,样本量有限。
- 纯化重组CALR突变蛋白仅部分模拟CALR突变的效应,机制尚未完全阐明。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Congenital amegakaryocytic thrombocytopenia (CAMT) is a severe inherited thrombocytopenia due to loss-of-function mutations affecting the thrombopoietin (TPO) receptor, MPL. Here, we report a new homozygous MPL variant responsible for CAMT in 1 consanguineous family. The propositus and her sister presented with severe thrombocytopenia associated with mild anemia. Next-generation sequencing revealed the presence of a homozygous MPLR464G mutation resulting in a weak cell-surface expression of the receptor in platelets. In cell lines, we observed a defect in MPLR464G maturation associated with its retention in the endoplasmic reticulum. The low cell-surface expression of MPLR464G induced very limited signaling with TPO stimulation, leading to survival and reduced proliferation of cells. Overexpression of a myeloproliferative neoplasm-associated calreticulin (CALR) mutant did not rescue trafficking of MPLR464G to the cell surface and did not induce constitutive signaling. However, it unexpectedly restored a normal response to eltrombopag (ELT), but not to TPO. This effect was only partially mimicked by the purified recombinant CALR mutant protein. Finally, the endogenous CALR mutant was able to restore the megakaryocyte differentiation of patient CD34+ cells carrying MPLR464G in response to ELT.
引用
- Basso-Valentina F, Levy G, Varghese LN, et al. CALR mutant protein rescues the response of MPL p.R464G variant associated with CAMT to eltrombopag. Blood. 2021. PMID: 34010413. doi:10.1182/blood.2020010567
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。